Life sciences landscape intelligence
A cited map of the science,
the trials, and the money.
Terrane maps the life sciences landscape: every company, asset, clinical trial, investor, and partnership, connected and cited, organized by the science. The landscape that took your team a quarter to build now maintains itself.
- Understand
- Open one company for its programs, trials, backers, and partners, or open an indication for everyone in it. Same map either way, searchable by the science.
- Decide
- Every relationship carries the source it came from and the snippet it was read out of, so the answer holds up in front of an investment committee or a board.
- Act
- Financings, readouts, and licenses reach the map as they are published, so you see a move while there is still something to do about it.
Market map
Your market map updates itself as the evidence lands.
Every cell resolves from cited events, so there is no manual research step between the question and the picture. Size a field, find who else is in it, or brief a team from the same view. This is one plate of many.
Cardiometabolic: private companies by stage
Plate 04 · auto-generated · continuously updatedSmall molecule
4 financed this year · 2 stealth syndicates detected
Gene therapy
1 clinical hold in adjacent target class
Peptide / GLP-adjacent
Syndicate overlap with 3 top-decile funds
RNA
2 licensing options signed since January
Small molecule
3 readouts due within two quarters
Heart failure
$430M raised across last 4 rounds
Lipid disorders
1 crossover round closed pre-readout
Devices + drug
M&A interest reported in trade press
Illustrative plate. Every cell is a live query. Companies, stage, capital, and syndicates resolve from cited events.See the full sample map →
In practice
Ask questions that cross
from the science to the money.
Three things that normally live in three different tools are one connected record here, so a single line of inquiry crosses all of them. Every answer shows its sources.
- Who else is developing for this indication, and how far along are they?
- Every company with a program in the indication, ordered by phase, with the trials and events behind each position.
- Which trials are running against my mechanism?
- Trials linked to targets, mechanisms, and modalities, so a competing approach surfaces even when it is filed under a different label.
- Who has treated this condition before, and what happened to those programs?
- Program histories including the discontinuations, so the graveyard is part of the landscape instead of a gap in it.
- Who funds this science, and who do they co-invest with?
- Investors mapped by what they actually funded: modality, stage, and indication, with syndicates and repeat pairings visible.
- Which Phase 2 assets in my indication have no large-pharma partner?
- Partnership and licensing status is a first-class field, so unpartnered assets are a filter rather than a research project.
- What changed in my field this week?
- Financings, readouts, licenses, and program changes across everything you track, the day they land, with sources attached.
Investors, business development, corporate strategy, competitive intelligence, and founders all work the same map. The difference is which question you arrive with.
Exploration
Find the connections
nobody thought to look for.
A question rarely ends where it started. Every answer here is somewhere you can keep moving from, and what turns out to matter is often two or three steps past the first search: the founder who has done this before, the investor who was early in a competing program, the licensing deal that explains why a company went quiet.
- Start from anything
- A company, a program, a trial, an investor, or the people behind them. Whatever you are looking at, everything attached to it is one step away.
- Keep pulling
- From a company to the trials it is running, from a trial to the investor who came in before the readout, from that investor to everything else it has backed in your indication. You never go back to a search box.
- See what links two things
- Ask what connects a company and an investor, or two companies working the same target, and get the chain between them: a shared founder, a common licensor, someone who sat on both sides.
- Keep the receipts
- Every step shows where it came from and quotes the line it was taken from, so something you found several steps in is still something you can put in front of a committee.
The system
Screen the field, brief the
meeting, watch for change.
Six capabilities behind those three jobs. Each replaces something you currently assemble by hand, and each keeps itself current after you close the tab.
Filter by what determines value
Indication, mechanism of action, modality, clinical phase, trial status, partnership and licensing terms. The dimensions life sciences actually turns on, all first-class.
Any company, one cited page
Financing history, syndicate, pipeline, trials, and partners, assembled automatically from cited events and current as of this morning. Ready before your next meeting.
See how the field connects
Syndicate maps, co-investor patterns, licensing chains, and the people who move between companies. The context that explains how a field arrived where it is, and where it moves next.
Plain questions, computed answers
“Which Phase 3 programs target this pathway?” or “Which funds led ADC rounds within 90 days of a positive Phase 2?” Answered from the map in seconds, with every source shown, not free-associated by a chatbot.
Alerts on what you track
Follow companies, investors, targets, or whole indications. A financing, readout, or license in your field reaches you the day it happens, with sources attached.
Every fact traceable to a document
Each relationship stores its source and verbatim snippet. Put the answer in front of an investment committee or a board without caveats.
Versus generalist databases
The science is the data model.
Generalist deal databases file a biotech under "Industry: Biotechnology" and move on. In life sciences, the value lives in what they don't model: the indication, the mechanism, the trial, the partnership. That's the data model here, not an add-on.
| Dimension | Generalist databases | Terrane |
|---|---|---|
| Classification | Industry tags and keywords | ■Indication, mechanism of action, modality |
| Clinical context | Not modeled | ■Trials, phases, and readouts linked to every company |
| Deal detail | Rounds and amounts | ■Plus licensing structure, options, milestones, partnership status |
| A real question | Keyword search, then a week of spreadsheets | ■One query: “Phase 2 ADCs without a large-pharma partner” |
| Trust | “Source: proprietary” | ■Citation and snippet on every relationship |
Early access
Put your market
on the map.
We're onboarding a first cohort of life sciences investors, business development and corporate strategy teams, competitive intelligence groups, and founders. Tell us the indications you cover, and we'll open your view of Terrane.